Plasminogen Activator Inhibitor-1 4G/5G (rs1799889) Polymorphism in Chinese Patients with Diabetes Mellitus and Hypertension.

Diabetes Metab Syndr Obes

Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

Published: April 2023

Objective: To determine the plasminogen activator inhibitor-1 (PAI-1) 4G/5G (rs1799889) genotype of the subjects in a robust detection method and to explore the association of the 4G/5G polymorphism with susceptibility to diabetes mellitus (DM) and hypertension (HTN) as well as clinical characteristics.

Methods: This study recruited 208 patients (68 patients were diagnosed with DM, 70 patients with HTN and 70 patients with DM combined with HTN) and 132 healthy controls (HC). A subset of the population was selected to evaluate the accuracy of the Real-time PCR (RT-PCR) method for detecting 4G/5G polymorphism by using the sequencing method as the gold standard. Furthermore, the association of the 4G/5G polymorphism with genetic susceptibility to DM and HTN was explored. Moreover, variations in clinical characteristics among individuals with various genotypes were also analyzed in the DM group, the HTN group and the DM+HTN group.

Results: There was a high concordance between the RT-PCR method and the sequencing method in determining the 4G/5G polymorphism. No association was observed between the 4G/5G polymorphism and susceptibility to DM, HTN and DM+HTN, respectively. There were no statistical differences in all study indicators among individuals that carrying various genotypes in the HC group. There were several variations in clinical characteristics among individuals harboring different 4G/5G genotypes in the DM group, the HTN group and the DM+HTN group.

Conclusion: The RT-PCR method can accurately identify the 4G/5G genotype in different individuals. The 4G/5G polymorphism may not be associated with genetic susceptibility to DM, HTN and DM+HTN, but differences in clinical characteristics among individuals with various genotypes may provide a reference for disease assessment and personalized treatment of patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132305PMC
http://dx.doi.org/10.2147/DMSO.S410682DOI Listing

Publication Analysis

Top Keywords

4g/5g polymorphism
24
rt-pcr method
12
susceptibility htn
12
clinical characteristics
12
characteristics individuals
12
4g/5g
10
plasminogen activator
8
activator inhibitor-1
8
4g/5g rs1799889
8
diabetes mellitus
8

Similar Publications

Systemic sclerosis (SSc) is characterized by a complex interplay of vascular damage, inflammation, and fibrosis, affecting the skin and internal organs. Plasminogen activator inhibitor-1 (PAI-1), a protein encoded by the gene, is a potential biomarker of SSc because it is primarily involved in fibrinolysis and is associated with the severity of some autoimmune diseases. This study aimed to determine the association between variant -675 4G/5G and soluble PAI-1 (sPAI-1) levels with the clinical characteristics and risk of SSc in a Mexican population.

View Article and Find Full Text PDF

A Nomogram Model Containing Genetic Polymorphisms to Predict Risk of Pulmonary Embolism in Pregnant Women.

Int J Womens Health

September 2024

Department of Critical Care Medicine, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Fudan, 200031, People's Republic of China.

Introduction: Pulmonary embolism (PE), the most serious presentation of venous thromboembolism (VTE), is associated with a high rate of mortality and expense. Clinical studies on pregnant women with PE are scarce. The aim of this study was to analyze the clinical impact of fibrinolytic enzyme activation inhibitor-1 (PAI-1) 4G/5G genetic polymorphisms, methylenetetrahydrofolate reductase (MTHFR) rs1801131 (A1298C) and rs1801133 (C677T) genetic polymorphisms, and establish a predictive model for pregnant women.

View Article and Find Full Text PDF

Association between PAI-1 4G/5G genotype and residual thrombus in acute mesenteric venous thrombosis.

Mol Biol Rep

September 2024

Department of Vascular Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.

Objective: Plasminogen activator inhibitor-1 (PAI-1) is the most important inhibitor of plasminogen activator. The functional 4G/5G polymorphism of the gene coding for PAI-1 may affect PAI-1 plasmatic activity, influencing the imbalance between coagulation and fibrinolysis cascades. In this study, we investigated the association between the PAI-1 4G/5G genotype and the development and residual thrombus of acute primary mesenteric venous thrombosis (MVT).

View Article and Find Full Text PDF

Background/aim: We aimed to determine the genetic risk factors in patients aged 45 years and below with a history of early myocardial infarction (MI), compared to individuals over 60 years of age with no history of MI.

Materials And Methods: In this study, we selected different age groups to more clearly distinguish genetic differences. Accordingly, we compared individuals who had experienced MI at an early age with those who were older and had not experienced any cardiovascular events.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores the link between specific gene polymorphisms (ABCB1 C3435T and PAI-1 4G/5G) and adverse reactions induced by glucocorticoids (GCs) in nephrotic syndrome (NS) patients.
  • In a sample of 513 NS patients, the researchers found that ABCB1 C3435T was a risk factor for steroid-induced avascular necrosis of the femoral head (SANFH), while PAI-1 4G/5G was linked to both SANFH and steroid diabetes mellitus (S-DM).
  • The study suggests that testing for these gene variants before starting GC treatment could help identify
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!